SCHEMBL10102234

SCHEMBL10102234

Oc1cc2ccccc2c2c1CCc1ccccc1-2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.43
TRPM4 Q8TD43 1/20 0.43
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
BCHE P06276 2/20 0.40
ACHE P22303 2/20 0.40
HTR1A P08908 1/20 0.40
HTR7 P34969 1/20 0.40
ALOX5 P09917 1/20 0.40
NQO2 P16083 1/20 0.38
DAPK3 O43293 1/20 0.36
PRKD3 O94806 1/20 0.36
PRKCG P05129 1/20 0.36
PRKCB P05771 1/20 0.36
PRKCA P17252 1/20 0.36
PRKCH P24723 1/20 0.36
PRKCI P41743 1/20 0.36
MAP3K9 P80192 1/20 0.36
PRKCE Q02156 1/20 0.36
MAP3K10 Q02779 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7784188 0.85 TRPM4 (0.44) TRPM4KDM4EALDH1A1BCHEACHE
SCHEMBL10102358 0.84 DRD2 (0.41) DRD2KDM4EALDH1A1
SCHEMBL10102357 0.82 S1PR1 (0.37) DRD2TRPM4KDM4EALDH1A1HTR1A
SCHEMBL16139579 0.81 KDM4E (0.40) DRD2KDM4EALDH1A1BCHEACHE
SCHEMBL10102360 0.81 ALOX5 (0.44) DRD2KDM4EALDH1A1ACHEALOX5
SCHEMBL10106883 0.81 ACHE (0.51) KDM4EACHEALOX5MAP3K9MAP3K10
SCHEMBL13880266 0.79 DRD2 (0.46) DRD2KDM4EALDH1A1
SCHEMBL12952274 0.77 MAP3K9 (0.40) KDM4EALDH1A1BCHEACHEHTR1A
SCHEMBL13880445 0.76 DRD2 (0.43) DRD2KDM4EALDH1A1
SCHEMBL27631807 0.75 HTR1A (0.53) KDM4EALDH1A1BCHEACHEHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8308995-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2012-11-13 US disclosed
US-8308995-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2012-11-13 US disclosed
EP-2275418-B1 CHROMENE COMPOUND TOKUYAMA CORP (JP) 2012-10-17 EP disclosed
US-20120138876-A1 CHROMENE COMPOUND KASAI SOKO (JP) 2012-06-07 US disclosed
US-20120138876-A1 CHROMENE COMPOUND KASAI SOKO (JP) 2012-06-07 US disclosed
US-8147726-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2012-04-03 US disclosed
US-8147726-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2012-04-03 US disclosed
US-20110062396-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2011-03-17 US disclosed
US-20110062396-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2011-03-17 US disclosed
EP-2275418-A1 CHROMENE COMPOUND Tokuyama Corporation (JP) 2011-01-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120138876-A1 CHROMENE COMPOUND CHRM1, CBX8, CBX7 DRD2 412/4885TRPM4 2123/4885KDM4E 1435/4885
US-20110062396-A1 CHROMENE COMPOUND CDYL, NR0B1, NR1H2 DRD2 742/4885TRPM4 4223/4885KDM4E 2629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.